Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06566898

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients

Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions:

1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ? 2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ? 3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Mei Kang

Shanghai, Shanghai Municipality, 200080, China

Location status: Recruiting

Location contact

Dapeng Wang, PhD

SUB_INVESTIGATOR

Jiang Du, PhD

SUB_INVESTIGATOR

Lehao Ren, PhD

SUB_INVESTIGATOR

Mei Kang, MPH

CONTACT

[email protected]

+8618501709576

Ruilan Wang, PhD

SUB_INVESTIGATOR

Shan Gao, Master

PRINCIPAL_INVESTIGATOR

Xue Tian, Master

SUB_INVESTIGATOR

About this study

This is a historical prospective obsevational study. Patients diagnosed with severe and mild pneumonia are recruited continously from four hospitals (Shanghai General Hospital, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuhan Union Hospital, and Huanggang Central Hospital) in China during March, 2019 to March, 2025.

Next-generation sequencing: Metagenomics and metatranscriptomic libraries undergo next-generation sequencing using the Illumina Novaseq 6000 platform.

Microbiome analysis: using KneadData (v0.10.0) reference from the human genome (GRCH38 reference database) to filter out the quality control of illumina sequencing data in Virosaurus download virus genome data sets for reference, bowtie2 (v2.3.4.1) (genome coverage >30%, depth >1X) was used to locate and analyze the post-host sequence, and then the "samtools idxstats" command was used to calculate the classification and relative abundance of viruses. Meanwhile, in order to obtain the annotation information of bacteria at the species level, PhyloFlash (v3.4) was used to calculate read counts for 16S rRNA genes in the SILVA database, selecting similarity greater than or equal to 98% as a threshold. Using eukaryotic pathogen genome database EUPATHDB46 as reference, bowtie2 and samtools were used for qualitative and quantitative analysis of fungal pathogens.

The criteria for determining the cause of respiratory infection are: (1) existing species known to be associated with human disease (ICD-10), (2) previously unidentified potential novel pathogens (only DNA and RNA viruses whose genera or families have previously been shown to infect mammals), and (3) possible symbiotic bacteria not included.

Analysis of AMR: by comparing the sequence similarity between the sequencing fragments and known drug resistance genes, the detection content can determine whether drug resistance genes exist, and suggest drug resistance caused by modification, inactivation, repression and other drug resistance genes.

Drug resistance genes detection: genes related to drug resistance recorded in CARD (Comprehensive Antibiotic Resistance Database) and ARG-ANNOT database. In this assay, only functional genes with drug resistance activities such as modification, inactivation, and repression, as well as pathway and target changes caused by some point mutations, were reported.

Genetic diversity was computed as the mean pairwise genetic distance within a group. Maximum likelihood phylogenetic trees were constructed using RaxML with a general time-reversible nucleotide substitution model and 1000 bootstraps. The genetic distance between sequences was calculated using MEGAX, with a bootstrap method for variance estimation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.
  • Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.

Exclusion criteria

  • Patients whose biological samples may be contaminated;
  • Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.

Treatment and study plan

Primary outcomes

  1. Microbiome composition

    Time frame: during the study period, 2019-2025

    a collection of microbial communities detected in the biospecimen

Secondary outcomes

  1. Alpha diversity

    Time frame: during the study period, 2019-2025

    the diversity within a particular area or ecosystem

  2. Prevalence of bacterial resistance genes

    Time frame: during the study period, 2019-2025

    the number of bacterial resistance genes divided by the number of biospecimen

  3. Beta diversity

    Time frame: during the study period, 2019-2025

    a comparison of of diversity between ecosystems, usually measured as the amount of species change between the ecosystems

Study contacts

Contact information is provided by the study sponsor or research team.

Mei Kang, MPH

CONTACT

[email protected]

18501709576

Xue Tian, Master

CONTACT

[email protected]

02163240090

Sponsors and collaborators

Lead sponsor

Shanghai General Hospital, China

Other

Collaborators

  • The Central Hospital of Huanggang
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Wuxi People's Hospital Affiliated to Nanjing Medical University

Registry information

Official study title

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 22, 2024
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.